Nitrazepam for Periodic Movements in Sleep (Sleep-related Myoclonus)

Harvey Moldofsky, Carole Tullis, Grace Quance and Franklin A. Lue

ABSTRACT: In a follow-up study (mean, approximately six months), nitrazepam was helpful in suppressing periodic movements in sleep (sleep-related myoclonus) and improving disturbed sleep physiology and daytime symptoms of 13 patients (mean age - 53 yr).

RESUME: Le nitrazepam dans les mouvements périodiques pendant le sommeil (myoclonies du sommeil) Nous démontrons, à la suite d'une étude suivie pour au moins 6 mois, que le nitrazepam est utile pour supprimer les mouvements périodiques observés pendant le sommeil (myoclonies du sommeil) et pour améliorer la physiologie troublé du sommeil et les symptômes diurnes chez 13 patients (âge moyen 53 ans).


Sleep-related (nocturnal) myoclonus or periodic movements in sleep (PMS) are periodic, involuntary, stereotyped movements of the lower limbs that typically occur at 20- to 40-sec intervals during sleep. PMS has been found in 13.3% of disorders of initiating and maintaining sleep (insomnia) and 6.9% of disorders of excessive daytime somnolence among 6,422 patients investigated by polysomnography. The disorder is found in 18% of the aged; accompanies certain medical disorders including end stage renal disease, rheumatic pain modulation disorder or “fibrositis syndrome”; restless legs syndrome and may be associated with sleep-related disorders, narcolepsy and cataplexy; and sleep apnea. The etiology of this disorder is unknown. Anecdotal reports have suggested varying successful treatment with folic acid, iron supplement, an alpha-receptor blocking agent, and several benzodiazepine medications, e.g., lorazepam, temazepam, and several with clonazepam. Symptomatic effects on those patients with daytime somnolence or insomnia and follow-up studies have not been systematically reported with any of these drugs.

In this paper we report on the efficacy of nitrazepam in controlling PMS and sleep-related and daytime symptoms in patients with either chronic insomnia or excessive daytime somnolence. Nitrazepam was selected because it is a benzodiazepine, structurally similar to clonazepam, has an elimination half-life somewhat shorter (15 to 38 hr) than clonazepam (18 to 50 hr), and, like clonazepam, has been shown to be effective in the treatment of myoclonic epilepsy.

MATERIALS AND METHOD

Thirteen patients who had been investigated with medical and psychiatric examinations for complaints of excessive daytime somnolence (EDS, N = 8) or intractable disorder of initiating and maintaining sleep (DIMS, N = 5) were found by polysomnography to have PMS. The patients (10 males, 3 females, mean age 53.3 yr) had their disorders for a mean of 7.3 years (S.D., 9.8). None of the patients had any other sleep-related disorder. Within the group, there were a variety of medical disorders: two had essential hypertension; one had a residual mild left-sided stroke; one had partial complex epilepsy controlled by phenytoin; one had iron deficiency anemia associated with menorrhagia treated by ferrous sulphate; one had coronary artery disease, chronic low back and lower limb pain; and one had no associated medical or psychiatric disorder. They had not received any hypnotic, tranquilizer or antidepressant medication for at least two weeks prior to the initial, or baseline, sleep study. If indicated, they continued with their antihypertensive, cardiac, or antacid medications.

Sleep studies were carried out in a sound-attenuated bedroom over one night. During the previous day, neither alcohol, caffeine substances, nor naps were permitted. Sleep recordings consisted of electroencephalogram (EEG) C3-A2 and C4-A1.
electro-oculogram (EOG), submental electromyogram (EMG) and electrocardiogram (EKG). Surface EMG recordings were obtained from the lower limbs over anterior tibialis muscles. Sleep recordings were scored in 40-sec epochs according to standard criteria. Leg activity was tabulated separately for each limb: leg jerks were counted when anterior tibialis EMGs showed activity bursts of 0.5 to 4.0 sec in duration with a periodicity ranging between 5 and 120 sec and following the criteria suggested in the Diagnostic Classification of Sleep and Arousal Disorders. To adjust for variable total sleep time for each subject the mean number of EMG bursts of activity per hour of sleep was calculated for each leg, and the leg with the higher number was used for comparison. Also calculated as means per hour of sleep were: number of movement arousals, number of wakens after sleep onset, and number of sleep stage changes. Percent time was calculated for wakefulness after sleep onset, stages 1, 2, 3, 4, Non Rapid Eye Movement (NREM) sleep and Rapid Eye Movement (REM) sleep.

Self ratings immediately before and after sleep were made of pain and stiffness in 10 specific body regions, on a scale of 0-6 in severity and totalled from all regions (scale of 0-60 severity). Sleepiness was assessed on a scale of 0-6 in severity using the Stanford Sleepiness Scale. Physical fatigue was similarly rated on a scale of 0 (none) to 6 (totally exhausted).

The patients were prescribed nitrazepam 5 mgm tablets 45 min before bedtime, and were advised to avoid all alcoholic and caffeine-containing beverages. They were followed on an outpatient basis for initial adjustment of their medication upwards to a maximum of 10 mgm or downwards to a minimum of 2.5 mgm. They were maintained at a constant individualized dose to provide optimal symptomatic relief and minimize any untoward effects. A night of polysomnography was performed at a mean time symptoms, mean 3.4 (S.D., 0.8). Furthermore, the 2 patients with fibrositis syndrome and the 3 patients with end stage renal disease experienced improvement in musculoskeletal pain (p<.05). Only one patient experienced untoward effects with the drug. She complained of some sluggishness and impaired daytime concentration. After five months she stopped the nitrazepam and her nocturnal restlessness and insomnia recurred.

**DISCUSSION**

Nitrazepam has been shown to be helpful in reducing nocturnal leg jerks and improving the sleep physiology of patients with PMS. Pre- and post-sleep laboratory self-ratings of fatigue and sleepiness were unchanged, but the global self-ratings of sleep quality and daytime symptoms were very much improved. While the study does not include a placebo-control group, patients are usually unaware of the periodic movements during sleep and this disorder is chronic, remains fairly stable, or is progressive with age. The coincident improvement in musculoskeletal pain, especially in the 2 patients with "fibrositis syndrome" and sleep-related myoclonus, is in accord with the previous studies of an association between an NREM EEG arousal disorder and musculoskeletal pain in such patients. All 3 patients with end stage renal disease treated by peritoneal dialysis who complained of severe insomnia, daytime exhaustion and widespread nonarticular musculoskeletal aching were remarkably improved, without change to the metabolic state associated with their disease. The moderate fatigue and sleepiness experienced upon awakening in the morning probably relate to the continued sedative effect of nitrazepam, but the symptoms dissipated early in the morning and did not prove troublesome except in one patient. This observation is consistent with the patients' global self-ratings and previous clinical reports of uncommon residual daytime sedative complaints.

### Table 1: Sleep measures at baseline versus treatment with nitrazepam

<table>
<thead>
<tr>
<th></th>
<th>All Patients (n = 13)</th>
<th>TREATMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>BASELINE</td>
<td>TREATMENT</td>
</tr>
<tr>
<td></td>
<td>Mean s.d.</td>
<td>Mean s.d.</td>
</tr>
<tr>
<td>Total Sleep Time (Hr)</td>
<td>5.16 1.63</td>
<td>6.33b 1.17</td>
</tr>
<tr>
<td>Latency to Stage 2 onset (min)</td>
<td>21.99 10.93</td>
<td>24.72 18.58</td>
</tr>
<tr>
<td>Latency to REM onset (min)</td>
<td>112.15 66.64</td>
<td>107.40 53.70</td>
</tr>
<tr>
<td>% Stage 1</td>
<td>7.89 5.30</td>
<td>5.56 2.38</td>
</tr>
<tr>
<td>% Stage 2</td>
<td>39.62 11.92</td>
<td>58.50c 8.95</td>
</tr>
<tr>
<td>% Stage 3</td>
<td>6.48 4.00</td>
<td>8.88 5.68</td>
</tr>
<tr>
<td>% Stage 4</td>
<td>6.15 7.30</td>
<td>2.91* 4.49</td>
</tr>
<tr>
<td>% REM</td>
<td>13.26 5.76</td>
<td>14.96 5.30</td>
</tr>
<tr>
<td>Sleep Efficiency (%)</td>
<td>71.78 17.08</td>
<td>86.81b 10.60</td>
</tr>
<tr>
<td>% Stage Wake</td>
<td>after sleep onset</td>
<td>26.11 17.92</td>
</tr>
<tr>
<td>Movement arousals</td>
<td></td>
<td>8.72c 7.51</td>
</tr>
<tr>
<td>Sleep stage changes</td>
<td></td>
<td>10.29 5.37</td>
</tr>
<tr>
<td>Wakenings*</td>
<td>12.22 4.27</td>
<td>8.10c 2.26</td>
</tr>
<tr>
<td>Wakenings*</td>
<td>2.78 2.12</td>
<td>1.28b 0.76</td>
</tr>
<tr>
<td>Higher no. of leg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EMG bursts*</td>
<td>59.43 41.75</td>
<td>21.07c 16.96</td>
</tr>
</tbody>
</table>

* number per hour of sleep
a .05<p<.10
b p<.05
c p<.01
d p<.002

Having excellent overall improvement in sleep quality and daytime symptoms, mean 3.4 (S.D., 0.8). Furthermore, the 2 patients with fibrositis syndrome and the 3 patients with end stage renal disease experienced improvement in musculoskeletal pain (p<.05). Only one patient experienced untoward effects with the drug. She complained of some sluggishness and impaired daytime concentration. After five months she stopped the nitrazepam and her nocturnal restlessness and insomnia recurred.

### RESULTS

After approximately six months of treatment with nitrazepam all 13 patients showed reduced leg jerks during sleep, increased percentage of stage 2 sleep and sleep efficiency (proportion of time asleep to time in bed) (see Table 1). Nitrazepam was also effective in improving sleep disturbance as indicated by a reduction in movement arousals, sleep stage changes and awakenings from sleep. Further, nitrazepam reduced the percent of wakefulness after sleep onset and tended to increase the duration of sleep (see Table 1).

There was no overnight difference in self ratings of moderate fatigue and sleepiness in the 5 patients complaining of insomnia, and the 8 patients complaining of daytime sleepiness. The latter group required less medication (mean dose 2.8 mgm) than those in the insomnia group (mean dose 7.8 mgm, p<.02). At follow-up, the patients continued to describe moderate fatigue and sleepiness before and after polysomnography. However, in the independent clinical assessment they rated themselves as globally having excellent overall improvement in sleep quality and daytime symptoms, mean 3.4 (S.D., 0.8). Furthermore, the 2 patients with fibrositis syndrome and the 3 patients with end stage renal disease experienced improvement in musculoskeletal pain (p<.05). Only one patient experienced untoward effects with the drug. She complained of some sluggishness and impaired daytime concentration. After five months she stopped the nitrazepam and her nocturnal restlessness and insomnia recurred.

### DISCUSSION

Nitrazepam has been shown to be helpful in reducing nocturnal leg jerks and improving the sleep physiology of patients with PMS. Pre- and post-sleep laboratory self-ratings of fatigue and sleepiness were unchanged, but the global self-ratings of sleep quality and daytime symptoms were very much improved. While the study does not include a placebo-control group, patients are usually unaware of the periodic movements during sleep and this disorder is chronic, remains fairly stable, or is progressive with age. The coincident improvement in musculoskeletal pain, especially in the 2 patients with "fibrositis syndrome" and sleep-related myoclonus, is in accord with the previous studies of an association between an NREM EEG arousal disorder and musculoskeletal pain in such patients. All 3 patients with end stage renal disease treated by peritoneal dialysis who complained of severe insomnia, daytime exhaustion and widespread nonarticular musculoskeletal aching were remarkably improved, without change to the metabolic state associated with their disease. The moderate fatigue and sleepiness experienced upon awakening in the morning probably relate to the continued sedative effect of nitrazepam, but the symptoms dissipated early in the morning and did not prove troublesome except in one patient. This observation is consistent with the patients' global self-ratings and previous clinical reports of uncommon residual daytime sedative complaints.
While nitrazepam does have a moderately prolonged elimination half-life and tends to accumulate in the plasma with regular dosing until a steady state is reached, there is no clear association between plasma concentration of the drug and daytime performance in young and elderly subjects.\(^\text{17}\)

Because the disorder has been identified in a variety of medical and sleep-related disorders, PMS has been suggested to be a non-specific feature of fragmented or disordered sleep.\(^\text{18}\) The neuromotor mechanism that provokes the appearance of this disorder during sleep is unknown. The daytime symptoms may relate to the influence of involuntary leg jerks on sleep physiology. The fact that suppression of leg jerks and improvement in sleep efficiency by nitrazepam remedies daytime complaints implies a connection between the frequency of sleep-related limb movements and associated sleep fragmentation to daytime symptoms.

A double-blinded placebo-controlled study with cross-over would further clarify the specificity of this medication. The reason for the beneficial effect of nitrazepam and similar benzodiazepines for PMS-related disorders must await further elucidation of the possibility of the existence of multiple benzodiazepine receptors and certain classes of benzodiazepines having selective CNS receptor and behavioral effects.\(^\text{19}\) Information on the specific central nervous system functions affected by nitrazepam would contribute to knowledge of the etiology of this ubiquitous, troublesome, common sleep disorder.

**ACKNOWLEDGEMENTS**

We thank M. Gupta, M.D., for assistance, L. Laws for secretarial help, D.G. Oreopoulos, M.D., D.A. Gordon, M.D. and J. Reynolds, M.D. of the Department of Medicine of the Toronto Western Hospital for referring many of the patients.

The study was supported by the Medical Research Council of Canada Grant No. MA-7733.

**REFERENCES**

1. Diagnostic Classification of sleep and arousal disorders: Association of Sleep Disorders Centres and the Association for the Psycho-physiological Study of Sleep, 1st ed. Sleep 1979; 2.